April 22nd 2024
In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Four-Year Follow-Up Data Confirm Durable Responses With CAR T-Cell Therapy in B-Cell Lymphomas
August 7th 2019In an interview with <em>Targeted Oncology</em>, Chong, a fellow at the University of Pennsylvania, discussed the 4-year follow-up data for CAR T cells in patients with DLBCL and FL. She also addressed the challenges that need to be overcome in order to give more patients access to this type of therapy.
Read More
FDA Grants Fast Track Designation to CLR 131 in DLBCL
July 10th 2019The FDA has granted a fast track designation for CLR 131 as a potential treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. The designation was based on data from the DLBCL cohort of the ongoing phase II CLOVER-1 trial which is investigating CLR 131 in patients with relapsed/refractory B-cell lymphomas.
Read More
Frontline Treatment With Lenalidomide Plus R-CHOP May Benefit Select Patients With DLBCL
June 27th 2019Lenalidomide plus standard R-CHOP immunochemotherapy may help select patients with activated B-cell-type diffuse large B-cell lymphoma who have a poor prognosis, based on data from the phase III ROBUST trial presented at the 2019 International Conference on Malignant Lymphoma.<br />
Read More
Sophisticated Risk Assessment and Prophylactic Strategies Needed for CNS Relapse in DLBCL
June 19th 2019Diffuse large B-cell lymphoma is the most common adult non-Hodgkin lymphoma, accounting for about a third of all cases. The World Health Organization classification recognizes over 15 subtypes of DLBCL, based on the primary tumor site, specific genetic alterations, or association with specific viruses.
Read More
Polatuzumab Vedotin Combo Approved by FDA for R/R DLBCL
June 10th 2019Polatuzumab vedotin in combination with bendamustine and rituximab has been granted an accelerated approval from the FDA for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.<br />
Read More
PFS Not Improved With Frontline Lenalidomide/R-CHOP Combo in DLBCL
May 2nd 2019Combining lenalidomide with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.
Read More
Novel CD19-Targeted Antibody Moves Toward Regulatory Filing in DLBCL
March 11th 2019A novel Fc-enhanced CD19-targeted antibody, MOR208, is generating interest for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for high-dose chemotherapy and autologous stem cell transplantation and is making its way toward a future regulatory filing.
Read More
Researchers Identify New Subtype of DLBCL, Develop Assay to Stratify Risk
March 8th 2019Researchers have defined a clinically and biologically distinct subgroup of tumors within germinal center B-cell–like diffuse large B-cell lymphoma characterized by a gene expression signature of high-grade B-cell lymphoma with <em>MYC </em>and <em>BCL2 </em>and/or <em>BCL6 </em>rearrangements, according to a study published in the <em>Journal of Clinical Oncology</em>.
Read More
Expert Highlights Early Efficacy Seen With Mosunetuzumab in Follicular Lymphoma and DLBCL
February 28th 2019In an interview with <em>Targeted Oncology </em>during the 2018 ASH Annual Meeting, Elizabeth Lihua Budde, MD, PhD, discussed the results seen from this trial for patients with FL and DLBCL. She shared plans for the next steps and how this treatment may impact the patient population.
Read More
Based on data from the phase III AUGMENT trial, a supplemental new drug application for the R<sup>2</sup> regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.
Read More
Reduced-dose rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone had a similar complete response rate, progression-free survival, and overall survival compared with standard-dose R-CHOP or previous dose-adjusted R-CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma.
Read More
Polatuzumab Vedotin Granted Priority Review Designation by FDA for DLBCL
February 19th 2019Polatuzumab vedotin, an antibody-drug conjugate that has demonstrated a 40% complete response rate in patients with relapsed/refractory diffuse large B-cell lymphoma, has been granted a priority review designation by the FDA in combination with bendamustine and rituximab for the treatment of these patients, according to Genentech, the manufacturer of the agent.
Read More
Maziarz Highlights Impact of Tisagenlecleucel in DLBCL
January 24th 2019Updated data from the JULIET trial, which were presented at the 2018 ASH Annual Meeting, underscore the impact of tisagenlecleucel for patients with diffuse large B-cell lymphoma, said Richard T. Maziarz, MD, the trial's lead investigator.
Read More